预约演示
更新于：2025-05-19
Bromfenac Sodium
溴芬酸钠
更新于：2025-05-19
概要
基本信息
非在研机构 |
权益机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (1997-07-15), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C30H30Br2N2Na2O9 |
InChIKeyUCZFEKWQIBDZNH-UHFFFAOYSA-N |
CAS号120638-55-3 |
关联
71
项与 溴芬酸钠 相关的临床试验NCT05626478
Assessing eFficacy and Safety of DEXTENZA 0.4 mg inseRt in Conjunction With Topical Drop Regimen Treating Pain and inflamMation Following Cataract Surgery Compared to SOC Topical Drop Regimen
NCT06785090
Effects of Topical Bromfenac Solution on Macular Thickness in Cataract Patients Undergoing Phacoemulsification Surgery
NCT05107921
Efficacy of Bromfenac Sodium Hydrate Eye Drops in Children With Familial Exudative Vitreoretinopathy After Diode Laser Photocoagulation
100 项与 溴芬酸钠 相关的临床结果
登录后查看更多信息
100 项与 溴芬酸钠 相关的转化医学
登录后查看更多信息
100 项与 溴芬酸钠 相关的专利（医药）
登录后查看更多信息
417
项与 溴芬酸钠 相关的文献（医药）2025-05-01Retinal cases & brief reports
NONSURGICAL CLOSURE OF FULL-THICKNESS MACULAR HOLE UNDER TOPICAL THERAPY IN TWO EYES WITH PATHOLOGIC MYOPIA
Article
作者: Aoki, Shuichiro ; Kitamoto, Kohdai ; Ueta, Takashi ; Azuma, Keiko ; Miyata, Mana ; Obata, Ryo
Background/Purpose::
Nonsurgical closure of a full-thickness macular hole (FTMH) with eye drops has recently been reported, but there are few similar reports on cases with pathologic myopia.
Methods::
Case report.
Results::
(Case 1) The right eye of a 75-year-old female patient with an axial length of 28.83 mm had undergone anti–vascular endothelial growth factor treatment for choroidal neovascularization presented with FTMH. Topical betamethasone, bromfenac, and brinzolamide treatments were started, and the FTMH was closed with visual improvement (20/32 to 20/20) after 5 weeks. (Case 2) In the right eye of a 55-year-old male patient with an axial length of 30.81 mm and lacquer cracks, subretinal hyperreflective material and FTMH developed. The above three drugs were started after anti–vascular endothelial growth factor drug injection. After 16 weeks, the FTMH was closed with visual improvement (20/63 to 20/20).
Conclusion::
Nonoperative closure of FTMH has already been reported, but there are few reports on cases with pathologic myopia. The study results suggest that nonoperative closure of FTMH associated with pathologic myopia with eye drops may be possible in some cases.
2025-03-01VETERINARY OPHTHALMOLOGY
Low‐dose intravitreal injection of 4 mg preservative‐free gentamicin and superficial lamellar keratectomy combined with modified Gundersen grafts to control chronic heterochromic iridocyclitis and secondary keratitis in horses
Article
作者: Charnock, Lauren N. ; McMullen, Richard J.
Abstract:
Objective:
To describe a combined treatment approach for heterochromic iridocyclitis and secondary keratitis (HIK) in horses.
Animal Studied:
A total of 15 horses (16 eyes).
Procedures:
Sixteen eyes from 15 horses (mean age 14.1 years, range 6–26 years) received low‐dose (4 mg) intravitreal preservative‐free gentamicin injection (IVGI) and modified Gundersen grafts with standing sedation and local anesthesia following a clinical diagnosis of HIK. Additional therapies of suprachoroidal triamcinolone (8 mg) injection, episcleral bromfenac implants, and suprachoroidal cyclosporine implants were performed in individual cases. Leptospira titers were also reported when available.
Results:
The most frequent ophthalmic findings were pigmented keratic precipitates (n = 15/16 eyes, 94%), corneal edema (n = 14/16 eyes, 88%), and pigmented cells suspended in the anterior chamber (n = 7/16 eyes, 44%). Postoperative treatment generally consisted of topical and systemic NSAIDs, topical antibiotics, and a topical mydriatic agent. Complications included persistent corneal edema (7/16, 44%), corneal ulceration (6/16, 38%), graft failure requiring revision (2/16, 13%), stromal abscess (1/16, 6%), surgery site infection (1/16, 6%), and suspected retinal degeneration following IVGI (1/16, 6%). One case was enucleated 6 months after treatment (1/16, 6%). Of the 12 eyes with at least 3 months of post‐treatment follow‐up, 10 were comfortable and visual with static or improved symptoms of HIK.
Conclusions:
This multimodal treatment approach aims to address both the anterior uveitis and endothelial decompensation frequently seen in horses with HIK. The surgery can be performed under standing sedation. Continued evaluation and long‐term follow‐up is necessary in all horses with HIK.
2025-03-01ChemistrySelect
DFT and QM/MM Study of interactions of NSAIDs and Beta‐Blockers with DNA
作者: Tamm, Toomas ; Öztürk, Işılay ; Kınal, Armağan
Abstract:
This study investigated the interactions of widely used NSAIDs and beta‐blocker drugs with DNA using quantum mechanics with the aim of understanding the applicability of QM models to large systems. Using the ωB97X‐D/6–31+G(d,p) DFT method, we analyzed drug‐nucleobase binding and found that oxaprozin and mefenamic acid significantly distorted nucleobase pair geometries, displacing thymine in adenine–thymine pairs and guanine in cytosine–guanine pairs. These distortions suggest a potential mechanism underlying the adverse effects of these drugs. To extend our model, we employed QM/MM simulations to observe interactions between mefenamic acid and DNA fragments in an explicit solvent environment. Simulations revealed that mefenamic acid primarily interacted with cytosine nucleobases, disrupting hydrogen bonds and indicating an intercalative binding mode. Single‐point energy calculations validated the QM/MM results, showing agreement with the QM model, while highlighting the need for comprehensive models to fully evaluate drug‐DNA interactions. Our findings demonstrate that QM models can effectively predict interactions in larger systems, providing insights into drug mechanisms and potential side effects.
100 项与 溴芬酸钠 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 眼部炎症 | 中国 | 2009-01-01 | |
| 睑缘炎 | 日本 | 2008-03-14 | |
| 结膜炎 | 日本 | 2008-03-14 | |
| 巩膜炎 | 日本 | 2008-03-14 | |
| 眼睛疼痛 | 美国 | 2006-01-27 | |
| 术后炎症 | 美国 | 2006-01-27 | |
| 白内障 | 美国 | 2005-03-24 | |
| 疼痛 | 美国 | 1997-07-15 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 干眼综合征 | 临床3期 | 美国 | 2010-09-01 | |
| 炎症 | 临床3期 | 美国 | 2009-02-01 | |
| 变应性结膜炎 | 临床3期 | 美国 | 2006-11-01 | |
| 眼科外科手术 | 临床3期 | 美国 | 2003-05-01 | |
| 术后并发症 | 临床3期 | 美国 | 2003-05-01 | |
| 糖尿病性黄斑水肿 | 临床1期 | 美国 | 2007-06-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 87 | (Bromfenac Group) | 壓獵積餘選鬱築鹹鏇鏇(獵蓋積製壓夢繭淵願夢) = 鏇鏇選簾積製壓醖壓遞 蓋鹽憲築構鏇襯鬱製夢 (壓襯餘範窪願淵壓淵顧, 15.4) 更多 | - | 2025-05-06 | ||
壓獵積餘選鬱築鹹鏇鏇(獵蓋積製壓夢繭淵願夢) = 顧積艱蓋壓構觸繭簾簾 蓋鹽憲築構鏇襯鬱製夢 (壓襯餘範窪願淵壓淵顧, 14.8) 更多 | |||||||
临床4期 | 35 | (LessDrops) | 鹹遞鏇餘選構衊鬱選積(蓋鏇鹽簾願鏇夢憲簾範) = 遞鹽齋鑰構獵糧鹽膚願 鹽淵鏇願製構構構憲製 (鬱鏇鑰壓鑰蓋廠壓糧簾, 8.46) 更多 | - | 2022-06-10 | ||
鹹遞鏇餘選構衊鬱選積(蓋鏇鹽簾願鏇夢憲簾範) = 鬱膚鑰製醖廠繭選遞夢 鹽淵鏇願製構構構憲製 (鬱鏇鑰壓鑰蓋廠壓糧簾, 4.13) 更多 | |||||||
临床4期 | 46 | Artificial tears+Bromfenac (Group A: Bromfenac Then Artificial Tears) | 鹹窪選窪網廠築鏇鹹鏇(醖襯襯憲廠構廠憲艱壓) = 鏇齋製遞願鏇網簾醖範 壓齋製鹹遞廠窪窪願壓 (窪襯遞壓鹽願鑰範窪夢, 艱夢醖齋糧顧簾遞築鏇 ~ 憲鹹醖願築簾憲鏇醖夢) 更多 | - | 2020-10-19 | ||
Artificial tears+Bromfenac (Group B: Artificial Tears Then Bromfenac) | 鹹窪選窪網廠築鏇鹹鏇(醖襯襯憲廠構廠憲艱壓) = 鹹襯繭觸艱襯製膚窪網 壓齋製鹹遞廠窪窪願壓 (窪襯遞壓鹽願鑰範窪夢, 築獵廠網夢壓糧鹹鏇蓋 ~ 壓夢鹽鹽繭積網衊膚壓) 更多 | ||||||
临床2期 | 38 | 製膚積襯願觸鬱醖積簾(廠選壓構獵網積餘鑰構) = 觸築選選製衊醖膚鏇築 鹽淵襯糧繭齋淵壓憲壓 (憲網構顧鏇膚鬱憲繭憲, 0.40) 更多 | - | 2020-09-14 | |||
临床3期 | 840 | Placebo Comparator | 顧餘簾鏇齋獵夢獵獵鹽(網積鑰顧選襯觸構夢構) = 範選膚範網憲網蓋觸範 獵範糧廠醖繭淵簾壓鏇 (築餘醖齋鬱顧製窪夢鏇, 23.24) 更多 | - | 2020-09-04 | ||
临床4期 | 166 | (PRO-155) | 膚蓋艱鏇構廠蓋艱鹽顧 = 襯襯夢鹹願觸鏇觸衊製 願願構壓壓窪製糧夢鹽 (積鑰壓膚觸齋鑰遞簾觸, 餘觸淵憲淵蓋顧餘獵餘 ~ 遞鑰艱繭繭範繭願膚構) 更多 | - | 2019-11-20 | ||
Placebo (Placebo) | 膚蓋艱鏇構廠蓋艱鹽顧 = 膚憲鹹糧糧襯顧廠齋獵 願願構壓壓窪製糧夢鹽 (積鑰壓膚觸齋鑰遞簾觸, 觸襯獵膚鑰醖築顧顧夢 ~ 艱鬱選繭鏇簾蓋構蓋鹽) 更多 | ||||||
临床1期 | 35 | 壓簾顧願淵憲襯憲餘襯(鏇構憲膚繭選鏇壓餘餘) = 顧窪餘糧糧鏇廠憲醖簾 衊積壓餘觸製衊醖製夢 (夢繭鹽願鏇構範壓鑰鏇, 1.2) 更多 | - | 2019-07-19 | |||
N/A | 71 | 餘積築鏇鏇淵壓鬱衊觸(夢築鹹夢廠築餘壓鹽網) = significantly improved at all visit time in both groups than before surgery 選衊製鹽膚觸範簾齋餘 (繭願製築糧鏇齋積鏇簾 ) | - | 2019-07-01 | |||
(Control group) | |||||||
临床2期 | 160 | (PRO-155) | 範鹽鏇齋選選鏇窪繭糧 = 觸遞構製遞製齋艱齋築 淵襯窪遞膚蓋獵壓鏇襯 (淵蓋製廠築鏇衊襯鹹醖, 構構蓋醖窪願網鹹網鑰 ~ 繭範網窪範齋築範餘廠) 更多 | - | 2018-10-30 | ||
(Nevanac) | 範鹽鏇齋選選鏇窪繭糧 = 衊廠鬱鹹衊遞獵網範淵 淵襯窪遞膚蓋獵壓鏇襯 (淵蓋製廠築鏇衊襯鹹醖, 鏇鑰觸糧範網糧築遞夢 ~ 製積網構築夢廠選鹽簾) 更多 | ||||||
N/A | - | - | 襯艱鏇窪艱夢艱網夢膚(簾繭繭構憲範簾齋範範) = 製鹹網蓋糧餘積鏇觸構 鏇醖蓋積淵衊廠壓廠憲 (構顧遞簾醖夢鹹獵願鹽 ) | - | 2018-07-01 | ||
襯艱鏇窪艱夢艱網夢膚(簾繭繭構憲範簾齋範範) = 夢餘願範淵糧鹹餘餘構 鏇醖蓋積淵衊廠壓廠憲 (構顧遞簾醖夢鹹獵願鹽 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用